PLD1 and Hodgkins lymphoma: To bypass this limitation, Ernst and coworkers have explored the effectiveness of combining CSL362 with human allogeneic NK cells to kill Hodgkin lymphoma cells showing that this combination was highly effective in killing CD123+ lymphoma cells and that CSL362 facilitated NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets in ARF6/PLD-1 [129].